By tying peptides originally distant in parental proteins, the proteasome can generate spliced peptides recognized by cytolytic T cells. Here, we study the production of six tumor-associated spliced peptides by the four proteasome subtypes: the standard proteasome (SP), the immunoproteasome (IP) and the intermediate proteasomes β5i (SIP) and β1iβ5i (DIP). Three of these peptides are better produced by SP while the other three are better produced by IP and DIP. The current model suggests that the production of a spliced peptide depends on the abundance of splice partners. Surprisingly, we have found that the efficiency of the peptide splicing reaction also appears to rely on the affinity of the nucleophilic peptide for the "prime" site of th...
CD8+ T cell specificity depends on the recognition of MHC class I-epitope complexes at the cell surf...
Peptides recognized by cytolytic T lymphocytes (CTL) on tumors usually originate from the degradatio...
In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-p...
By tying peptide fragments originally distant in parental proteins, the proteasome can generate spli...
By tying peptide fragments originally distant in parental proteins, the proteasome can generate spli...
The proteasome is the major protease responsible for the production of antigenic peptides recognized...
These past years, we focused our researches on the identification of novel, potential peptide target...
CD8+ cytolytic T lymphocytes are essential players of anti-tumor immune responses. On tumors, they r...
These past years, we focused our researches on the identification of novel, potential peptide target...
Peptide splicing allows the production of antigenic peptides composed of two fragments initially non...
Peptide splicing is a novel mechanism of production of peptides relying on the proteasome and involv...
Antigens presented by MHC class I molecules to CD8+ T lymphocytes consist of peptides of 8-11 amino ...
Protein degradation by the proteasome releases peptides that can be loaded on MHC class I molecules ...
The identification of proteasome-generated spliced peptides (PSP) revealed a new unpredicted activit...
CD8+ T cell specificity depends on the recognition of MHC class I-epitope complexes at the cell surf...
CD8+ T cell specificity depends on the recognition of MHC class I-epitope complexes at the cell surf...
Peptides recognized by cytolytic T lymphocytes (CTL) on tumors usually originate from the degradatio...
In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-p...
By tying peptide fragments originally distant in parental proteins, the proteasome can generate spli...
By tying peptide fragments originally distant in parental proteins, the proteasome can generate spli...
The proteasome is the major protease responsible for the production of antigenic peptides recognized...
These past years, we focused our researches on the identification of novel, potential peptide target...
CD8+ cytolytic T lymphocytes are essential players of anti-tumor immune responses. On tumors, they r...
These past years, we focused our researches on the identification of novel, potential peptide target...
Peptide splicing allows the production of antigenic peptides composed of two fragments initially non...
Peptide splicing is a novel mechanism of production of peptides relying on the proteasome and involv...
Antigens presented by MHC class I molecules to CD8+ T lymphocytes consist of peptides of 8-11 amino ...
Protein degradation by the proteasome releases peptides that can be loaded on MHC class I molecules ...
The identification of proteasome-generated spliced peptides (PSP) revealed a new unpredicted activit...
CD8+ T cell specificity depends on the recognition of MHC class I-epitope complexes at the cell surf...
CD8+ T cell specificity depends on the recognition of MHC class I-epitope complexes at the cell surf...
Peptides recognized by cytolytic T lymphocytes (CTL) on tumors usually originate from the degradatio...
In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-p...